← Leaderboards
Feng Guo
University Of California Los Angeles
$3,870,377
Attributed
$4,086,939
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $715K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,086,939 · 4
By mechanism
R01$3,650,408 · 2
R21$433,125 · 1
P41$3,406 · 1
Top collaborators
- M Carrie Miceli2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- April D Pyle$6,193,530
- Peggie Jane Chien$126,024
- Ivan Flores$114,270
- Dan S Ray$6,368,446
- Sean Curtis Bendall$22,064,188
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureComplexBiochemicalCellsBaseMutationDesignProteinsReportingIn VivoThree Dimensional StructureBiologicalBase PairingLifeLinkOligonucleotidesGenesAffinityMolecularClinical Trials3-DimensionalAntisense OligonucleotidesBindingAnimal Model
Grant awards (13)
Developing three-dimensional antisense oligonucleotide drugs against COVID-19$478,737
R01 · FY2025 · AI · contact PI
Structure-based antisense therapeutics targeting dystrophin exons 44 and 45 for Duchenne Muscular Dystrophy$196,875
R21 · FY2025 · HD · contact PI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19$478,737
R01 · FY2024 · AI · contact PI
Structure-based antisense therapeutics targeting dystrophin exons 44 and 45 for Duchenne Muscular Dystrophy$236,250
R21 · FY2024 · HD · contact PI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19$478,737
R01 · FY2023 · AI · contact PI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19$478,737
R01 · FY2022 · AI · contact PI
Developing three-dimensional antisense oligonucleotide drugs against COVID-19$426,633
R01 · FY2021 · AI · contact PI
Molecular recognition and regulation in microRNA processing by the DGCR8 protein$258,100
R01 · FY2011 · GM · contact PI
STRUCTURE OF THE DIMERIZATION DOMAIN OF DIGEORGE CRITICAL REGION 8$3,406
P41 · FY2011 · RR · contact PI
Molecular recognition and regulation in microRNA processing by the DGCR8 protein$260,707
R01 · FY2010 · GM · contact PI
Molecular recognition and regulation in microRNA processing by the DGCR8 protein$263,340
R01 · FY2009 · GM · contact PI
Molecular recognition and regulation in microRNA processing by the DGCR8 protein$263,340
R01 · FY2008 · GM · contact PI
Molecular recognition and regulation in microRNA processing by the DGCR8 protein$263,340
R01 · FY2007 · GM · contact PI